Biosimilars, also known as follow-on biologics, are the subsequent versions of innovative biological medicine that are introduced after the expiry of the original medicine's patent. The development of biosimilars is a complex and expensive process, but it has potential to improve the accessibility of life-saving treatments. Emerging technological trends in the biosimilar sector are redefining the way these medicines are developed, evaluated, and marketed. Given that India is a global hub for generic medicine, it is critical to examine the country's role in the rapidly evolving biosimilars landscape.
In recent years, the market for biosimilars or similar biologics, has seen significant expansion, particularly in India. India's biosimilars market size was valued at $349 million in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 25.2 per cent from 2022 to 2030 and will reach $2108 million by 2030.
India is one of the leading manufacturers of biosimilars, and has observed an increase in their use, improving the health of many patients suffering from a wide variety of diseases. The most significant advantage of biosimilars is that they cost less than the original drugs that they replicate.
An article noted that the expiration of patents on many key biologics by 2020 would provide a sizable opportunity for the development and use of biosimilars. With over one hundred biopharmaceutical companies engaged in the manufacturing and marketing of biosimilars, India has emerged as a global market leader in this segment. It was the first to approve a biosimilar back in 2000 for the treatment of hepatitis B- much before Europe and the United States.
Bu hikaye Bio Spectrum dergisinin August 2024 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye Bio Spectrum dergisinin August 2024 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Giriş Yap
Economic Survey Lays Focus On Mental Healthcare For The First Time
For the first time ever, the Economic Survey 2023-24 tabled by the Union Minister of Finance and Corporate Affairs Nirmala Sitharaman in Parliament recently, talks extensively about mental health, its significance and implications on policy recommendations.
IIT-G discovers RNA-destroying function of p30 protein in African Swine Fever Virus
Indian Institute of Technology Guwahati (IIT-G) researchers have investigated the biochemistry of the African Swine Fever Virus (ASFV) protein, focusing on understanding the biochemical processes of infection to devise effective control strategies.
13th Bengaluru INDIA NANO 2024 brings together 1018 delegates, 3,000+ visitors
The 13th edition of Bengaluru INDIA NANO 2024, organised by the Department of Science & Technology, Government of Karnataka, Karnataka Science & Technology Promotion Society (KSTePS), and Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) concluded on August 3 with participation of 1018 delegates, 11 countries including Korea, Morocco, USA, UK, France, Canada, Germany, Netherlands, Russia, Japan, and Poland, 49 exhibitors comprising 21 startups and 28 industry and institutes, and 200 posters. The exhibition had a footfall of 3,000+ visitors.
Are Nutraceuticals DRUGS? Examining a Needless Regulatory Tussle
The news has been around for a while which has put a big question mark ahead of the Indian nutraceuticals industry.
Can India Reclaim API Throne from China?
Despite having the third-largest pharmaceutical industry by volume in the world and being the largest manufacturer of generic medicines globally, India is heavily dependent on China for imports of raw materials, Key Starting Materials (KSMs), and Active Pharmaceutical Ingredients (APIs).
JRS Pharma & Gujarat Microwax open new manufacturing facility in Mehsana
JRS Pharma, a leading manufacturer of excipients, in partnership with Gujarat Microwax, has commissioned a new manufacturing facility for cotton-based croscarmellose sodium.
NovaLead's patented repurposed drug for treating DFU gets CDSCO approval
Pune-based NovaLead Pharma has announced that the drug regulator in India, Central Drugs Standard Control Organisation (CDSCO), has approved their patented Repurposed Drug for treatment of Diabetic Foot Ulcer (DFU) which is a global unmet medical need.
Medicamen Organics expands footprint in East Africa with $75,000 investment in Rwanda
Delhi-based pharma company Medicamen Organics has taken a significant step in its global expansion strategy by signing a Memorandum of Understanding (MoU) with Depot Pharmacy Yego in Rwanda.
Mankind Pharma acquires 100% stake in Bharat Serums and Vaccines for Rs 13,630 Cr
Mankind Pharma has entered into a definitive agreement to acquire a 100 per cent stake in Bharat Serums and Vaccines Limited (BSV) from Advent International, for an enterprise value of approx.
Thyrocare buys Polo Labs' pathology diagnostic biz to strengthen Northern India presence
Mumbai-based Thyrocare, a leading diagnostic and preventive healthcare service provider in India, has entered into a Business Transfer Agreement with Polo Labs to acquire their pathology diagnostic business.
